Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if adding a new drug that is targeted at a specific
genetic change found in some breast tumors pre-operatively will slow the growth of the tumor
more than standard anti-hormone therapy used to treat this type of breast cancer. Different
therapies are being tested based on the specific gene changes in the tumor. Not every tumor
will have a gene change that is being studied.